Biotech Life Sciences Industry Analysis

US Stocks: Apellis shares double on Biogen's $5.6 billion buyout plan

Biogen's $5.6B Apellis buyout signals M&A momentum in pharma, boosting Indian biotech talent demand and contract manufacturing opportunities.

Impact: 6/10